Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Partnering to build biosynthesis processes and a pharmaceutical production platform
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
A toll-free helpline to be set up to help doctors and patients
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Subscribe To Our Newsletter & Stay Updated
